29 Oct 2026

Slovakia has published Act No. 258/2026, completing the legislative passage of reforms to its medicine reimbursement system. The law was adopted on 6 October and promulgated on 29 October. Its main provisions amend Act No. 363/2011, with initial commencement on 1 November 2026 and other provisions taking effect later.

The reform revises the calculation of cost-effectiveness thresholds using gross domestic product per person. The framework provides for a multiple of up to three for standard medicines and up to ten for orphan medicines, paediatric indications and advanced therapies. The reference GDP figure will remain fixed for three years before revision by regulation. Additional evidence and reassessment conditions apply to specified medicines admitted without first meeting standard cost-effectiveness requirements.

Exceptional reimbursement is also moving towards clearer statutory entitlement and more uniform insurer decisions. Changes addressing this pathway are scheduled for January 2027, following criticism of divergent insurer practice and the previous expenditure cap.

For managed-entry agreements, the law adds conditions governing reimbursement limits and continuity of treatment, including obligations where an agreement is terminated. These provisions place stronger emphasis on predictable expenditure exposure and protection for patients already receiving treatment.

The new law advances the proposal covered by LiSAH in June from parliamentary consideration to enactment. Its practical effect will depend partly on implementing regulations and the phased commencement of the reimbursement and exceptional-access provisions.

Source: Slovak legal information portal, Slov-Lex
Link: Zákon č. 258/2026 Z. z., ktorým sa mení a dopĺňa zákon č. 363/2011 Z. z. o rozsahu a podmienkach úhrady liekov (Act No. 258/2026 amending Act No. 363/2011 on the scope and conditions of medicine reimbursement)
Date: 29 October 2026

Source: Public Defender of Rights, Slovakia
Link: Dnes som vzal späť svoj návrh Ústavnému súdu Slovenskej republiky vo veci liekov na výnimku. Novela účinná od 1. januára 2027 zohľadňuje mnou napadnuté výhrady (I have withdrawn my Constitutional Court application concerning medicines reimbursed by exception; the amendment effective from 1 January 2027 addresses my objections)
Date: 29 October 2026